126
|
Luo X, Tang M, Hu Q. Genomic DNA Methylation of Non-Small Cell Lung Cancer Applied in Early Screening of Tumour. Indian J Pharm Sci 2020. [DOI: 10.36468/pharmaceutical-sciences.spl.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
127
|
Luo X, Guo C, Yin H, Shi B, Yin X, Li J. Comparison of Hogan pharyngeal flap and sphincter pharyngoplasty in postoperative velopharyngeal function. Br J Oral Maxillofac Surg 2019; 58:291-295. [PMID: 31864856 DOI: 10.1016/j.bjoms.2019.11.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2019] [Accepted: 11/25/2019] [Indexed: 02/05/2023]
Abstract
The purpose of this study was to compare speech and breathing after sphincter pharyngoplasty and the Hogan pharyngeal flap in the management of cleft-related velopharyngeal insufficiency (VPI). We reviewed 78 patients with VPI who had either the Hogan flap (n=30) or sphincter pharyngoplasty (n=48) between 2009 and 2011. Velopharyngeal function, nasal patency, and speech were compared. In the Hogan flap group, 25 patients had achieved velopharyngeal competence and nine had normal speech. In the sphincter pharyngoplasty group, 29 patients achieved velopharyngeal competence and 20 normal speech. The Hogan flap group had a higher rate of velopharyngeal competence (n=25) than the sphincter pharyngoplasty group (p=0.033), but there was no significant difference in intelligibility of speech. Eighteen patients in the Hogan flap group and 33 in the sphincter pharyngoplasty group reported symptoms of snoring, with no significant difference in nasal ventilation. Our results suggest that a posterior pharyngeal flap is a more effective technique for managing VPI after repair of cleft palate than sphincter pharyngoplasty, and causes no more postoperative complications in nasal breathing.
Collapse
|
128
|
Qi SR, Cui YJ, Liu JX, Luo X, Wang HF. Lactobacillus rhamnosus GG components, SLP, gDNA and CpG, exert protective effects on mouse macrophages upon lipopolysaccharide challenge. Lett Appl Microbiol 2019; 70:118-127. [PMID: 31782817 DOI: 10.1111/lam.13255] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 11/22/2019] [Accepted: 11/25/2019] [Indexed: 12/17/2022]
Abstract
The aim of this study was to determine whether Lactobacillus rhamnosus GG (LGG) components (surface layer protein, SLP; genomic DNA, gDNA; unmethylated cytosine-phosphate-guanine-containing oligodeoxynucleotide, CpG-ODN), alone or in combination, could affect immunomodulation, and evaluate the signalling mechanism in mouse macrophage RAW264.7 cells challenged with lipopolysaccharide (LPS). LGG components were used to treat cells before LPS stimulation. Cytokine and Toll-like receptor (TLR) expression were assessed using real-time quantitative PCR (RT-qPCR). Mitogen-activated protein kinase (MAPK), extracellular regulated protein kinase (ERK) and nuclear factor-kappa B (NF-κB) signalling pathways were evaluated using immunoblots and immunofluorescence. SLP or SLP + gDNA pre-treatment significantly reduced the LPS-induced mRNA expression of tumour necrosis factor alpha (TNF-α). Pre-treatment with LGG single components (SLP, gDNA or CpG) or their combinations (SLP + gDNA or SLP + CpG) significantly decreased the LPS-induced interleukin-6 (IL-6) mRNA level (P < 0·05). Pre-treatment with SLP or gDNA, alone or in combination, significantly suppressed LPS-induced TLR2 and TLR4 mRNA levels (P < 0·05). SLP pre-treatment also significantly decreased the LPS-induced expression of TLR9 (P < 0·05). Pre-treatment with LGG single components or combinations significantly suppressed the LPS-induced phosphorylation levels of ERK (P > 0·05). In conclusion, pre-incubation with LGG components, singly or in combination, generally inhibited the activation of TLR, MAPK and NF-κB signalling pathways in LPS-stimulated cells, leading to attenuated inflammatory cytokine TNF-α and IL-6 production. These results indicate that nonviable probiotic LGG components exert an anti-inflammation effect on epithelial cells. SIGNIFICANCE AND IMPACT OF THE STUDY: Lactobacillus rhamnosus GG (LGG) is widely used as probiotics. However, its main components are not well known for affecting immunomodulation. This study investigated the effects of pre-treatments with different components such as surface layer protein, genomic DNA and unmethylated cytosine-phosphate-guanine-containing oligodeoxynucleotides, alone or in combination on immunomodulation, and evaluated the signalling mechanism in mouse macrophage RAW264.7 cells challenged with lipopolysaccharide. Pre-incubation with components alone or in combination generally inhibited the activation of Toll-like receptor, mitogen-activated protein kinases, extracellular regulated protein kinases and nuclear factor-kappa B signalling pathways in lipopolysaccharide-stimulated cells, which generally leads to attenuated inflammatory cytokine interleukin-6 and tumour necrosis factor alpha production. These results indicate that nonviable probiotic LGG components exert an anti-inflammation effect on epithelial cells.
Collapse
|
129
|
Sun Y, Tong W, Luo X. Possible magnetic correlation above the ferromagnetic phase transition temperature in Cr 2Ge 2Te 6. Phys Chem Chem Phys 2019; 21:25220-25225. [PMID: 31697301 DOI: 10.1039/c9cp04685b] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Cr2Ge2Te6 has recently emerged as a new two-dimensional ferromagnetic semiconductor (2DFMS) that is promising for spintronic applications. The origin of the ferromagnetism is a debatable point. In this study, ac/dc susceptibility and electronic spin resonance (ESR) measurements are performed to explore the origin of the ferromagnetism in Cr2Ge2Te6. Through the ac susceptibility scaling, the critical temperature TC = 62.84 K and δ = 5.24 from the critical isotherm, γ + β = 1.78 from the temperature dependence of the crossover line and γ = 1.43 from the temperature dependence of the susceptibility along the same line. Unlike Cr2Si2Te6 whose magnetism can be well described by the 2D-Ising model, Cr2Ge2Te6 cannot be simply described by a single theory model. Meanwhile, the origin of the abnormal critical behavior has been explored and it may be related to the presence of the possible magnetic correlation around the high temperature T* ∼ 160 K, which is confirmed by different probing measurements. The magnetic correlation at high temperature accompanied by the strong magnetic-crystalline anisotropy at low temperature plays an important role in the origin of the abnormal ferromagnetism in Cr2Ge2Te6. Our results may supply a typical reference to investigate the abnormal ferromagnetism of 2DFMSs.
Collapse
|
130
|
Roan N, Neidleman J, Luo X, Frouard J, Hsiao F, Xie G, Morcilla V, James K, Hoh R, Somsouk M, Hunt P, Deeks S, Archin N, Palmer S, Greene W. Single cell analysis of in vivo HIV reservoir uncovers novel markers of latent cells. J Virus Erad 2019. [DOI: 10.1016/s2055-6640(20)30073-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
131
|
Liao YJ, Zhao HT, Jiang Y, Ma YK, Luo X, Li XY. An innovative method based on cloud model learning to identify high-risk pollution intervals of storm-flow on an urban catchment scale. WATER RESEARCH 2019; 165:115007. [PMID: 31450219 DOI: 10.1016/j.watres.2019.115007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 08/14/2019] [Accepted: 08/19/2019] [Indexed: 06/10/2023]
Abstract
Identifying high-risk storm-flow pollution intervals in an urban watershed is critical for watershed pollution control decision-making. High-risk pollution intervals of storm-flow are defined as storm-flow intervals that contribute more than the background pollutant load, and whose load contribution rank in the top 20%. However, the identification of high-risk pollution intervals is difficult due to variations in the flow-concentration relationship among rain events, uncertainty inherent in stormwater quality data, and physically-based stormwater models requiring a substantial number of parameters. A new method for identifying high-risk pollution intervals during different rain events is proposed. A dataset of the urban watershed located in Shenzhen, southern China, was used to demonstrate the proposed method. A "cut-pool" strategy was initially used to pre-process the dataset for maximizing valuable information hidden in existing datasets and to investigate the impact of rainfall on flow-concentration relationships. Gaussian cloud distribution was then introduced to capture the trend, dispersing extent and randomness of stormwater quality data at any flow interval. Interval Overlapping Ratio (IOR) and Load contribution of storm-flow high-risk pollution intervals was used to assess the performance of the method. Results show that storm-flow high-risk Chemical Oxygen Demand (COD) pollution intervals of the Shiyan watershed was 0.5-1.5 mm under light rain (0-13 mm), 1-3 mm under moderate rain (13-27 mm) and 5-7 mm under heavy rain (27-43 mm). The accuracy of the identified high-risk pollution intervals (IOR) was 63-66% under light rain, 64-67% under moderate rain. Moreover, COD load can be reduced by 44-48% with high-risk storm-flow under light rain; 43-49% under moderate rain; 32% under heavy rain. This method is very useful for effectively controlling storm-flow pollution on an urban catchment scale.
Collapse
|
132
|
Fang R, Zhao NN, Zeng KX, Wen Q, Xiao P, Luo X, Liu XW, Wang YL. MicroRNA-544 inhibits inflammatory response and cell apoptosis after cerebral ischemia reperfusion by targeting IRAK4. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2019; 22:5605-5613. [PMID: 30229835 DOI: 10.26355/eurrev_201809_15825] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Stroke remains the most common malignant cerebrovascular event in the world. The correlation between the expression of miR-544 and the degree of cerebral ischemia reperfusion (CIR) injury has not been well recognized in recent years. This study focuses on the effect of miR-544 on inflammation and apoptosis after CIR. PATIENTS AND METHODS Plasma expression of miR-544 in ischemic stroke (IS) patients and healthy controls was determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). The effects of miR-544 on cerebral infarction and neurological deficits were verified in vitro by tail vein injection of Ago-miR-544. Western blotting was utilized to examine protein expressions of key proteins involving in inflammation and apoptosis in mouse brain. Western blotting, immunofluorescence staining and luciferase assays were used to demonstrate whether miR-544 influences the expression of interleukin-1 receptor-associated kinase 4 (IRAK4), downstream inflammatory and apoptosis-related proteins. RESULTS MiR-544 was found decreased in peripheral blood of IS patients compared with healthy controls. MiR-544 has been shown to relieve neurological deficits and reduce the volume of cerebral infarction in mice. Overexpression of miR-544 ameliorated the inflammation and apoptotic responses in brain tissue after ischemia reperfusion by down-regulating the expression of IRAK4, whereas the low expression was opposite in vivo and in vitro. CONCLUSIONS We found that miR-544 may participate in controlling inflammation and apoptosis after ischemia-reperfusion by targeting IRAK4, providing possible diagnostic indicators and therapeutic targets for IS.
Collapse
|
133
|
Luo X, Song Y, Tang L, Sun DH, Ji DG. LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2019; 22:7788-7797. [PMID: 30536320 DOI: 10.26355/eurrev_201811_16403] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To elucidate the biological functions of long non-coding RNA (lncRNA) SNHG7 in breast cancer (BC), and its underlying mechanism in the occurrence and progression of BC. PATIENTS AND METHODS The expression of SNHG7 in 72 pairs of BC tissues and paracancerous tissues was detected by quantitative Real-time polymerase chain reaction (qRT-PCR). Correlation between SNHG7 expressions with pathological indicators of BC patients was analyzed. Similarly, SNHG7 expression in BC cell lines was determined by qRT-PCR as well. After constructing the small inference RNA of SNHG7, cell proliferation, migration and invasion were determined by cell counting kit-8 (CCK-8), 5-Ethynyl-2'-deoxyuridine (EdU) and transwell assay. MicroRNA-186 expression in BC tissues and cells was accessed. Dual-luciferase reporter gene assay was conducted to verify the binding condition between SNHG7 and microRNA-186. RESULTS SNHG7 expression was higher in BC tissues than that of paracancerous tissues. High expression of SNHG7 was positively correlated to tumor stage, lymph node metastasis and distant metastasis, whereas not correlated to age, sex and tumor location of BC. Kaplan-Meier curves revealed that higher expression of SNHG7 is correlated to the worse prognosis of BC patients. SNHG7 was highly expressed in BC cells as well. Knockdown of SNHG7 inhibited proliferative, invasive and migratory abilities of BC cells. QRT-PCR data showed that microRNA-186 is lowly expressed in BC tissues compared with that of paracancerous tissues. MicroRNA-186 was lowly expressed in BC cells as well. Both mRNA and protein levels of microRNA-186 were negatively correlated to SNHG7 in BC tissues. Finally, the dual-luciferase reporter gene assay demonstrated that SNHG7 could be directly targeted by microRNA-186. CONCLUSIONS SNHG7 is highly expressed in BC, which is correlated to tumor stage, lymph node metastasis and distant metastasis of BC patients. SNHG7 could promote malignant progression of BC by regulating microRNA-186.
Collapse
|
134
|
Adam J, Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Anderson DM, Aoyama R, Aparin A, Aschenauer EC, Ashraf MU, Atetalla FG, Attri A, Averichev GS, Bairathi V, Barish K, Bassill AJ, Behera A, Bellwied R, Bhasin A, Bhati AK, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Brandenburg JD, Brandin AV, Bryslawskyj J, Bunzarov I, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Cebra D, Chakaberia I, Chaloupka P, Chan BK, Chang FH, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen JH, Chen X, Cheng J, Cherney M, Christie W, Contin G, Crawford HJ, Csanád M, Das S, Dedovich TG, Deppner IM, Derevschikov AA, Didenko L, Dilks C, Dong X, Drachenberg JL, Dunlop JC, Edmonds T, Elsey N, Engelage J, Eppley G, Esha R, Esumi S, Evdokimov O, Ewigleben J, Eyser O, Fatemi R, Fazio S, Federic P, Fedorisin J, Feng Y, Filip P, Finch E, Fisyak Y, Fulek L, Gagliardi CA, Galatyuk T, Geurts F, Gibson A, Gopal K, Greiner L, Grosnick D, Gupta A, Guryn W, Hamad AI, Hamed A, Harris JW, He L, Heppelmann S, Heppelmann S, Herrmann N, Holub L, Hong Y, Horvat S, Huang B, Huang HZ, Huang SL, Huang T, Huang X, Humanic TJ, Huo P, Igo G, Jacobs WW, Jena C, Jentsch A, Ji Y, Jia J, Jiang K, Jowzaee S, Ju X, Judd EG, Kabana S, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Khyzhniak YV, Kikoła DP, Kim C, Kinghorn TA, Kisel I, Kisiel A, Kocan M, Kochenda L, Kosarzewski LK, Kramarik L, Kravtsov P, Krueger K, Kulathunga Mudiyanselage N, Kumar L, Kunnawalkam Elayavalli R, Kwasizur JH, Lacey R, Landgraf JM, Lauret J, Lebedev A, Lednicky R, Lee JH, Li C, Li W, Li W, Li X, Li Y, Liang Y, Licenik R, Lin T, Lipiec A, Lisa MA, Liu F, Liu H, Liu P, Liu P, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo S, Luo X, Ma GL, Ma L, Ma R, Ma YG, Magdy N, Majka R, Mallick D, Margetis S, Markert C, Matis HS, Matonoha O, Mazer JA, Meehan K, Mei JC, Minaev NG, Mioduszewski S, Mishra D, Mohanty B, Mondal MM, Mooney I, Moravcova Z, Morozov DA, Nasim M, Nayak K, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nogach LV, Nonaka T, Odyniec G, Ogawa A, Oh S, Okorokov VA, Page BS, Pak R, Panebratsev Y, Pawlik B, Pawlowska D, Pei H, Perkins C, Pintér RL, Pluta J, Porter J, Posik M, Pruthi NK, Przybycien M, Putschke J, Quintero A, Radhakrishnan SK, Ramachandran S, Ray RL, Reed R, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Salur S, Sandweiss J, Schambach J, Schmidke WB, Schmitz N, Schweid BR, Seck F, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Shen F, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Siejka S, Sikora R, Simko M, Singh J, Singha S, Smirnov D, Smirnov N, Solyst W, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stefaniak M, Stewart DJ, Strikhanov M, Stringfellow B, Suaide AAP, Sugiura T, Sumbera M, Summa B, Sun XM, Sun Y, Sun Y, Surrow B, Svirida DN, Szelezniak MA, Szymanski P, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Tawfik A, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Tsai OD, Tu B, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vasiliev AN, Vassiliev I, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang P, Wang Y, Wang Y, Webb JC, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu Y, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu YF, Xu Z, Yang C, Yang Q, Yang S, Yang Y, Yang Z, Ye Z, Ye Z, Yi L, Yip K, Zbroszczyk H, Zha W, Zhang D, Zhang L, Zhang S, Zhang S, Zhang XP, Zhang Y, Zhang Z, Zhao J, Zhong C, Zhou C, Zhu X, Zhu Z, Zurek M, Zyzak M. First Observation of the Directed Flow of D^{0} and D^{0}[over ¯] in Au+Au Collisions at sqrt[s_{NN}]=200 GeV. PHYSICAL REVIEW LETTERS 2019; 123:162301. [PMID: 31702332 DOI: 10.1103/physrevlett.123.162301] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2019] [Revised: 08/09/2019] [Indexed: 06/10/2023]
Abstract
We report the first measurement of rapidity-odd directed flow (v_{1}) for D^{0} and D^{0}[over ¯] mesons at midrapidity (|y|<0.8) in Au+Au collisions at sqrt[s_{NN}]=200 GeV using the STAR detector at the Relativistic Heavy Ion Collider. In 10-80% Au+Au collisions, the slope of the v_{1} rapidity dependence (dv_{1}/dy), averaged over D^{0} and D^{0}[over ¯] mesons, is -0.080±0.017(stat)±0.016(syst) for transverse momentum p_{T} above 1.5 GeV/c. The absolute value of D^{0} meson dv_{1}/dy is about 25 times larger than that for charged kaons, with 3.4σ significance. These data give a unique insight into the initial tilt of the produced matter, and offer constraints on the geometric and transport parameters of the hot QCD medium created in relativistic heavy-ion collisions.
Collapse
|
135
|
Luo X, Wei YQ, Hai L, Hu YC, Zhao ZJ, Ma WL, Ma LN, Liu XY, Ding XC. [A preliminary study of serum marker alpha-enolase in the diagnosis of hepatocellular carcinoma]. ZHONGHUA GAN ZANG BING ZA ZHI = ZHONGHUA GANZANGBING ZAZHI = CHINESE JOURNAL OF HEPATOLOGY 2019; 27:505-510. [PMID: 31357775 DOI: 10.3760/cma.j.issn.1007-3418.2019.07.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the diagnostic value of serum α-enolase (ENO1) in the primary hepatocellular carcinoma. Methods: From May 2012 to March 2017, 163 cases with liver diseases who met the inclusion and exclusion criteria were admitted to the Infectious Diseases Department of the General Hospital of Ningxia Medical University. Among them, 28 cases were of chronic hepatitis B (CHB), 31 cases with liver cirrhosis (LC), 104 cases with hepatocellular carcinoma (HCC), and 18 healthy volunteers (NC). Patient data and serum samples were collected and liver disease related indicators were measured to detect ENO1 levels with enzyme-linked immunosorbent assay (ELISA). The measured indicators were expressed in median. Mann-Whitney U nonparametric test was used to analyze the differences between the data. A Spearman's correlation analysis was used for bivariate correlation analysis. The sensitivity and specificity of ENO1 and alpha-fetoprotein in the diagnosis of liver cancer were analyzed by ROC curve. Results: Serum level of ENO1 in CHB group, LC group and HCC group was significantly higher than normal group. Serum level of ENO1 in HCC group was higher than CHB group (P = 0.001) and LC group (P < 0.01). Area under the curve (AUC) for serum ENO1 and alpha-fetoprotein were 0.782 (cut-off value 75.96, P = 0.000 1) and 0.800 (cut-off value 27.02, P = 0.000 1), respectively. There was a positive correlation between ENO1 and AFP (P = 0.001). The combined detection had significantly improved the detection efficiency (AUC = 0.835). Serum ENO1 was statistically significant (P < 0.05) in HCC tumor size (AUC = 0.663), tumor metastasis (AUC = 0.681), TNM stage (AUC = 0.710, stage I vs. II), and Edmondson grade (AUC = 0.685) (P < 0.05) and the elevated levels of ENO1 had significantly reduced (P < 0.05) the survival time. Conclusion: ENO1 can be a new candidate marker for the diagnosis of early stage HCC and its progression.
Collapse
|
136
|
Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Jiang J, Di Fusco M, B Garcia Reeves A, Yuce H, Lip GYH. P4794Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The ARISTOPHANES (Anticoagulants for Reduction In STroke: Observational Pooled analysis on Health outcomes ANd Experience of patientS) study showed that non-vitamin K antagonist oral anticoagulants (NOACs) were associated with lower risks of stroke/systemic embolism (S/SE) and variable comparative risks of major bleeding (MB) versus warfarin.
Purpose
To assess long-term use of non-VKA oral anticoagulants (NOACs) vs. warfarin in
ARISTOPHANES by evaluating the risk of S/SE and MB among non-valvular atrial fibrillation (NVAF) patients by duration of treatment (<1 and ≥1 year).
Methods
In the ARISTOPHANES study, NVAF patients initiating apixaban, dabigatran, rivaroxaban, or warfarin from 01/01/2013–09/30/2015 were identified from the CMS Medicare data and four US commercial claims databases, covering >180 million beneficiaries annually (∼56% of US population). After 1:1 propensity score matching (PSM) in each database between NOACs and warfarin (apixaban-warfarin, dabigatran-warfarin, and rivaroxaban-warfarin), the resulting patient records were pooled. Treatment duration was defined as time between the day after the treatment index date and discontinuation (30 days after a 30-day gap in the prescription), treatment switch, death, end of study period, or end of continuous medical and pharmacy enrollment, whichever occurred first. Matched patients with observed treatment duration <1 or ≥1 year were separately examined. Cox models were used to estimate hazard ratios of S/SE and MB (identified by inpatient claims) during observed treatment duration.
Results
The mean treatment duration for patients with shorter (<1 year) vs longer (≥1 year) duration was 4–5 months vs 18–21 months across the three matched cohorts. All the matched baseline variables remained balanced. The incidence rates of S/SE and MB and the proportion of patients with treatment discontinuation were higher in patients with shorter treatment duration. Regardless of treatment duration, apixaban patients had a lower risk of S/SE and MB versus warfarin; dabigatran patients had a lower risk of MB versus warfarin; and rivaroxaban patients had a lower risk of S/SE versus warfarin. Compared to warfarin patients, dabigatran patients with treatment duration <1 year had a similar risk of S/SE, while those with treatment duration ≥1 year had lower S/SE risk; rivaroxaban patients with treatment duration <1 year had a higher risk of MB, while those with treatment duration ≥1 year had similar MB risk.
Conclusions
Among NVAF patients with duration of treatment <1 and ≥1 year in the ARISTOPHANES study, apixaban and rivaroxaban were associated with lower risk of S/SE, while apixaban and dabigatran were associated with lower risk of MB, compared to warfarin. These findings indicate varying long-term effectiveness and safety outcomes between NOACs and warfarin.
Acknowledgement/Funding
This study was funded by Bristol-Myers Squibb and Pfizer Inc.
Collapse
|
137
|
Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Jiang J, Di Fusco M, B Garcia Reeves A, Yuce H, Lip GYH. P4768Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The ARISTOPHANES (Anticoagulants for Reduction In STroke: Observational Pooled analysis on Health outcomes ANd Experience of patientS) study showed that apixaban was associated with lower risks of stroke/systemic embolism (S/SE) and major bleeding (MB) versus dabigatran and rivaroxaban; dabigatran was associated with similar risk of S/SE and lower risk of MB compared to rivaroxaban.
Purpose
To assess long-term use of non-VKA oral anticoagulants (NOACs) in ARISTOPHANES by evaluating the risk of S/SE and MB among non-valvular atrial fibrillation (NVAF) patients receiving different NOACs by duration of treatment (<1 and ≥1 year).
Methods
In the ARISTOPHANES study, NVAF patients initiating apixaban, dabigatran, and rivaroxaban from 01/01/2013–09/30/2015 were identified from the CMS Medicare data and four US commercial claims databases, covering >180 million beneficiaries annually (∼56% of US population). After 1:1 propensity score matching (PSM) in each database between NOACs (apixaban-dabigatran, apixaban-dabigatran, and dabigatran-rivaroxaban), the resulting patient records were pooled. Treatment duration was defined as time between the day after the index treatment date and discontinuation (defined using a 30-day gap in the prescription), treatment switch, death, end of study period, or end of continuous medical and pharmacy enrollment, whichever occurred first. Matched patients with observed treatment duration <1 or ≥1 year were separately examined. Cox models were used to estimate hazard ratios of S/SE and MB (identified by inpatient claims) during observed treatment duration. S/SE included ischemic stroke, hemorrhagic stroke, and SE; MB included gastrointestinal (GI) bleeding, intracranial hemorrhage (ICH), and other MB.
Results
The mean treatment duration for patients with shorter (<1 year) vs longer (≥1 year) duration was ∼4 months vs 18–21 months across the three matched cohorts. All the matched baseline variables remained balanced. The incidence rates of S/SE and MB and the proportion of patients with treatment discontinuation were higher in patients with shorter treatment duration. Regardless of treatment duration, apixaban and dabigatran had a lower risk of MB versus rivaroxaban; and dabigatran had a similar risk of S/SE versus rivaroxaban. Compared to dabigatran patients, apixaban patients with treatment duration <1 year had a lower risk of S/SE and MB, while those with treatment duration ≥1 year had similar S/SE and MB risk. Compared to rivaroxaban patients, apixaban patients with treatment duration <1 year had a lower risk of S/SE, while those with treatment duration ≥1 year had similar S/SE risk.
Conclusions
Across NVAF patients with duration of treatment <1 and ≥1 year in the ARISTOPHANES study, both apixaban and dabigatran were associated with a lower risk of MB compared to rivaroxaban. These findings indicate varying long-term safety outcomes among different NOACs.
Acknowledgement/Funding
This study was funded by Bristol-Myers Squibb and Pfizer Inc.
Collapse
|
138
|
Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Sun X, Luo X. P5589Patterns of extended apixaban treatment for unprovoked venous thromboembolism in routine clinical practice. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Current CHEST guidelines recommend extended anticoagulation therapy without a scheduled stop in patients with unprovoked VTE and low bleeding risk following initial anticoagulation treatment of 3 months. AMPLIFY-EXT suggests that extended treatment with apixaban beyond 6 months reduces the risk of recurrent VTE without increasing major bleeding rates. This study evaluated patterns of extended apixaban treatment among unprovoked VTE patients.
Methods
Utilizing 4 US commercial claims databases, this retrospective study assessed unprovoked VTE patients (VTE events that were not preceded by a provoked factor or event) who initiated apixaban within 30 days from the VTE event (01SEPT2014–31MAR2018). Patients were required to have ≥6 months continuous apixaban treatment (without a gap of >30 days). Characteristics of patients treated beyond 6 months and those who discontinued at 6 months were evaluated respectively. An additional analysis was conducted to assess proportion with apixaban treatment for ≥3 months.
Results
Among unprovoked VTE patients, 60.8% and 34.6% had apixaban treatment for ≥3 and ≥6 months, respectively. Of those treated for ≥6 months (3,015 after applying additional selection criteria), 75.6% continued treatment beyond 6 months and 24.4% discontinued at 6 months. Younger age and having thrombophilia were associated with a higher likelihood of treatment beyond 6 months (Table). Among patients with treatment beyond 6 months, 7.5% of patients switched from apixaban 5mg to 2.5mg, 36.5% discontinued therapy, and 1.1% switched to another oral anticoagulant (Figure).
Baseline characteristics Variables Discontinued at 6 months Continued treatment beyond 6 months P-value N=735 N=2,280 Age, Mean (SD) 63.0 (15.2) 61.7 (14.3) 0.037 Gender – Female, n (%) 307 (41.8%) 892 (39.1%) 0.203 Setting of Unprovoked VTE Event – Ambulatory, n (%) 592 (80.5%) 1,834 (80.4%) 0.950 VTE Diagnosis – DVT Only, n (%) 494 (67.2%) 1,498 (65.7%) 0.452 Deyo-Charlson Comorbidity Index, Mean (SD) 1.3 (1.9) 1.3 (1.8) 0.305 Thrombophilia, n (%) 54 (7.3%) 296 (13.0%) <0.001 Coagulation Defects, n (%) 38 (5.2%) 153 (6.7%) 0.136 Baseline Bleed, n (%) 77 (10.5%) 210 (9.2%) 0.309
KM curve after 6 months of apixaban use
Conclusion
Among unprovoked VTE patients treated with apixaban, a large proportion did not receive ≥3 months of treatment. Although AMPLIFY-EXT showed beneficial effects of extended treatment, the percentage of patients with ≥6 months of treatment was low. Thrombophilia was the only meaningful predictor of treatment beyond 6 months.
Acknowledgement/Funding
This study was funded by Bristol-Myers Squibb and Pfizer Inc
Collapse
|
139
|
Jain R, Watzker A, Luo X, Kang A, Baker C, Rosenblatt L, Mardekian J, Menzin J. P3346Validation of obesity coding among newly-treated nonvalvular atrial fibrillation patients using an integrated electronic medical record and claims database. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Obesity is prevalent among patients with non-valvular atrial fibrillation (NVAF). Administrative claims databases offer the opportunity to evaluate obesity and morbid obesity in this patient population. However, there is limited information about the use and accuracy of diagnosis codes in claims data to identify obesity and morbid obesity among patients with NVAF.
Purpose
To evaluate the use and accuracy of diagnosis codes in claims data for identifying obesity and morbid obesity among newly-treated NVAF patients using a large geographically-diverse US database.
Methods
This retrospective study used Optum's de-identified integrated electronic medical record (EMR) and claims database (1/1/2013–3/31/2018). Adult (≥18 years) patients with ≥1 claim for an oral anticoagulant (OAC) from 1/1/2014–9/30/2017 were identified (treatment date as index date). Patients were required to have ≥1 atrial fibrillation diagnosis prior to the index date and were excluded if they had evidence of OAC use or valvular disease during the 12 months prior to the index date. Patients were required to have ≥12 months of continuous enrollment prior to and ≥6 months after the index date as well as ≥1 BMI measurement in the EMR data during the 6 months before or after the index date. Based on the World Health Organization's definition, patients were classified as obese if their BMI was ≥30 kg/m2 and morbidly obese if their BMI was ≥40 kg/m2. Sensitivity, specificity, and positive predictive value (PPV) were calculated to assess the accuracy of diagnosis codes for obesity (ICD-9 diagnosis codes: 278.00, 278.01, 278.03, V85.30-V85.39, V85.41-V85.45; ICD-10 diagnosis codes: E66.01, E66.09, E66.2, E66.8, E66.9, Z68.30-Z68.39, Z68.41-Z68.45) and morbid obesity (ICD-9 diagnosis codes: 278.01, V85.41-V85.45; ICD-10 diagnosis codes: E66.01, E66.2, Z68.41-Z68.45) commonly used in claims database research.
Results
There were 7,501 patients included in the newly-treated NVAF cohort (mean [±SD] age=72.4 [±10.7] years, 55% male, 90% white, and mean [±SD] Quan-Charlson Comorbidity Index =2.10 [±2.08]). Forty-six percent of these patients had BMI≥30 kg/m2, of whom about one-quarter (11% of the overall sample) had a BMI≥40 kg/m2. In contrast, 25% and 10% of patients had a diagnosis code for obesity or morbid obesity, respectively. For obesity diagnosis codes, sensitivity, specificity, and PPV were 49% (95% CI: 47%-50%), 95% (95%-96%), and 90% (88%-91%), respectively. For morbid obesity diagnosis codes, sensitivity, specificity, and PPV were 63% (59%-63%), 96% (96%-97%) and 68% (64%-71%), respectively.
Conclusion
Among newly-treated NVAF patients, obesity diagnosis codes in the claims database had high PPV, high specificity, and modest sensitivity. Morbid obesity diagnosis codes also had high specificity but modest PPV and sensitivity. These findings have implications for both case selection and control for obesity as a confounder in observational studies using a claims database.
Acknowledgement/Funding
The funding for the research project was provided by Pfizer Inc.
Collapse
|
140
|
Adam J, Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Anderson DM, Aoyama R, Aparin A, Arkhipkin D, Aschenauer EC, Ashraf MU, Atetalla F, Attri A, Averichev GS, Bairathi V, Barish K, Bassill AJ, Behera A, Bellwied R, Bhasin A, Bhati AK, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Brandenburg JD, Brandin AV, Bryslawskyj J, Bunzarov I, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Cebra D, Chakaberia I, Chaloupka P, Chan BK, Chang FH, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen JH, Chen X, Cheng J, Cherney M, Christie W, Crawford HJ, Csanád M, Das S, Dedovich TG, Deppner IM, Derevschikov AA, Didenko L, Dilks C, Dong X, Drachenberg JL, Dunlop JC, Edmonds T, Elsey N, Engelage J, Eppley G, Esha R, Esumi S, Evdokimov O, Ewigleben J, Eyser O, Fatemi R, Fazio S, Federic P, Fedorisin J, Feng Y, Filip P, Finch E, Fisyak Y, Fulek L, Gagliardi CA, Galatyuk T, Geurts F, Gibson A, Gopal K, Grosnick D, Gupta A, Guryn W, Hamad AI, Hamed A, Harris JW, He L, Heppelmann S, Heppelmann S, Herrmann N, Holub L, Hong Y, Horvat S, Huang B, Huang HZ, Huang SL, Huang T, Huang X, Humanic TJ, Huo P, Igo G, Jacobs WW, Jena C, Jentsch A, Ji Y, Jia J, Jiang K, Jowzaee S, Ju X, Judd EG, Kabana S, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Khyzhniak YV, Kikoła DP, Kim C, Kinghorn TA, Kisel I, Kisiel A, Kocan M, Kochenda L, Kosarzewski LK, Kramarik L, Kravtsov P, Krueger K, Kulathunga Mudiyanselage N, Kumar L, Kunnawalkam Elayavalli R, Kwasizur JH, Lacey R, Landgraf JM, Lauret J, Lebedev A, Lednicky R, Lee JH, Li C, Li W, Li W, Li X, Li Y, Liang Y, Licenik R, Lin T, Lipiec A, Lisa MA, Liu F, Liu H, Liu P, Liu P, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo S, Luo X, Ma GL, Ma L, Ma R, Ma YG, Magdy Abdelwahab Abdelrahman N, Majka R, Mallick D, Margetis S, Markert C, Matis HS, Matonoha O, Mazer JA, Meehan K, Mei JC, Minaev NG, Mioduszewski S, Mishra D, Mohanty B, Mondal MM, Mooney I, Moravcova Z, Morozov DA, Nasim M, Nayak K, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nogach LV, Nonaka T, Odyniec G, Ogawa A, Oh K, Oh S, Okorokov VA, Page BS, Pak R, Panebratsev Y, Pawlik B, Pawlowska D, Pei H, Perkins C, Pintér RL, Pluta J, Porter J, Posik M, Pruthi NK, Przybycien M, Putschke J, Quintero A, Radhakrishnan SK, Ramachandran S, Ray RL, Reed R, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Salur S, Sandweiss J, Schambach J, Schmidke WB, Schmitz N, Schweid BR, Seck F, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Shen F, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Siejka S, Sikora R, Simko M, Singh J, Singha S, Smirnov D, Smirnov N, Solyst W, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stefaniak M, Stewart DJ, Strikhanov M, Stringfellow B, Suaide AAP, Sugiura T, Sumbera M, Summa B, Sun XM, Sun Y, Sun Y, Surrow B, Svirida DN, Szymanski P, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tokarev M, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Tsai OD, Tu B, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vasiliev AN, Vassiliev I, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang P, Wang Y, Wang Y, Webb JC, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu Y, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu YF, Xu Z, Yang C, Yang Q, Yang S, Yang Y, Yang Z, Ye Z, Ye Z, Yi L, Yip K, Yoo IK, Zbroszczyk H, Zha W, Zhang D, Zhang L, Zhang S, Zhang S, Zhang XP, Zhang Y, Zhang Z, Zhao J, Zhong C, Zhou C, Zhu X, Zhu Z, Zurek M, Zyzak M. Polarization of Λ (Λ[over ¯]) Hyperons along the Beam Direction in Au+Au Collisions at sqrt[s_{NN}]=200 GeV. PHYSICAL REVIEW LETTERS 2019; 123:132301. [PMID: 31697517 DOI: 10.1103/physrevlett.123.132301] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 08/21/2019] [Indexed: 06/10/2023]
Abstract
The Λ (Λ[over ¯]) hyperon polarization along the beam direction has been measured in Au+Au collisions at sqrt[s_{NN}]=200 GeV, for the first time in heavy-ion collisions. The polarization dependence on the hyperons' emission angle relative to the elliptic flow plane exhibits a second harmonic sine modulation, indicating a quadrupole pattern of the vorticity component along the beam direction, expected due to elliptic flow. The polarization is found to increase in more peripheral collisions, and shows no strong transverse momentum (p_{T}) dependence at p_{T} greater than 1 GeV/c. The magnitude of the signal is about 5 times smaller than those predicted by hydrodynamic and multiphase transport models; the observed phase of the emission angle dependence is also opposite to these model predictions. In contrast, the kinematic vorticity calculations in the blast-wave model tuned to reproduce particle spectra, elliptic flow, and the azimuthal dependence of the Gaussian source radii measured with the Hanbury Brown-Twiss intensity interferometry technique reproduce well the modulation phase measured in the data and capture the centrality and transverse momentum dependence of the polarization signal.
Collapse
|
141
|
Abratenko P, Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Auger M, Balasubramanian S, Baller B, Barnes C, Barr G, Bass M, Bay F, Bhat A, Bhattacharya K, Bishai M, Blake A, Bolton T, Camilleri L, Caratelli D, Caro Terrazas I, Carr R, Castillo Fernandez R, Cavanna F, Cerati G, Chen Y, Church E, Cianci D, Cohen EO, Collin GH, Conrad JM, Convery M, Cooper-Troendle L, Crespo-Anadón JI, Del Tutto M, Devitt D, Diaz A, Domine L, Duffy K, Dytman S, Eberly B, Ereditato A, Escudero Sanchez L, Esquivel J, Evans JJ, Fitzpatrick RS, Fleming BT, Franco D, Furmanski AP, Garcia-Gamez D, Genty V, Goeldi D, Gollapinni S, Goodwin O, Gramellini E, Greenlee H, Grosso R, Gu L, Gu W, Guenette R, Guzowski P, Hackenburg A, Hamilton P, Hen O, Hill C, Horton-Smith GA, Hourlier A, Huang EC, James C, Jan de Vries J, Ji X, Jiang L, Johnson RA, Joshi J, Jostlein H, Jwa YJ, Karagiorgi G, Ketchum W, Kirby B, Kirby M, Kobilarcik T, Kreslo I, Lepetic I, Li Y, Lister A, Littlejohn BR, Lockwitz S, Lorca D, Louis WC, Luethi M, Lundberg B, Luo X, Marchionni A, Marcocci S, Mariani C, Marshall J, Martin-Albo J, Martinez Caicedo DA, Mason K, Mastbaum A, Meddage V, Mettler T, Mills J, Mistry K, Mogan A, Moon J, Mooney M, Moore CD, Mousseau J, Murphy M, Murrells R, Naples D, Nienaber P, Nowak J, Palamara O, Pandey V, Paolone V, Papadopoulou A, Papavassiliou V, Pate SF, Pavlovic Z, Piasetzky E, Porzio D, Pulliam G, Qian X, Raaf JL, Rafique A, Ren L, Rochester L, Rogers HE, Ross-Lonergan M, Rudolf von Rohr C, Russell B, Scanavini G, Schmitz DW, Schukraft A, Seligman W, Shaevitz MH, Sharankova R, Sinclair J, Smith A, Snider EL, Soderberg M, Söldner-Rembold S, Soleti SR, Spentzouris P, Spitz J, Stancari M, John JS, Strauss T, Sutton K, Sword-Fehlberg S, Szelc AM, Tagg N, Tang W, Terao K, Thomson M, Thornton RT, Toups M, Tsai YT, Tufanli S, Usher T, Van De Pontseele W, Van de Water RG, Viren B, Weber M, Wei H, Wickremasinghe DA, Wierman K, Williams Z, Wolbers S, Wongjirad T, Woodruff K, Wu W, Yang T, Yarbrough G, Yates LE, Zeller GP, Zennamo J, Zhang C. First Measurement of Inclusive Muon Neutrino Charged Current Differential Cross Sections on Argon at E_{ν}∼0.8 GeV with the MicroBooNE Detector. PHYSICAL REVIEW LETTERS 2019; 123:131801. [PMID: 31697542 DOI: 10.1103/physrevlett.123.131801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Revised: 08/06/2019] [Indexed: 06/10/2023]
Abstract
We report the first measurement of the double-differential and total muon neutrino charged current inclusive cross sections on argon at a mean neutrino energy of 0.8 GeV. Data were collected using the MicroBooNE liquid argon time projection chamber located in the Fermilab Booster neutrino beam and correspond to 1.6×10^{20} protons on target of exposure. The measured differential cross sections are presented as a function of muon momentum, using multiple Coulomb scattering as a momentum measurement technique, and the muon angle with respect to the beam direction. We compare the measured cross sections to multiple neutrino event generators and find better agreement with those containing more complete treatment of quasielastic scattering processes at low Q^{2}. The total flux integrated cross section is measured to be 0.693±0.010(stat)±0.165(syst)×10^{-38} cm^{2}.
Collapse
|
142
|
Adam J, Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Anderson DM, Aoyama R, Aparin A, Arkhipkin D, Aschenauer EC, Ashraf MU, Atetalla F, Attri A, Averichev GS, Bairathi V, Barish K, Bassill AJ, Behera A, Bellwied R, Bhasin A, Bhati AK, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Brandenburg JD, Brandin AV, Bryslawskyj J, Bunzarov I, Butterworth J, Caines H, Sánchez MCDLB, Cebra D, Chakaberia I, Chaloupka P, Chan BK, Chang FH, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen JH, Chen X, Cheng J, Cherney M, Christie W, Crawford HJ, Csanad M, Das S, Dedovich TG, Deppner IM, Derevschikov AA, Didenko L, Dilks C, Dong X, Drachenberg JL, Dunlop JC, Edmonds T, Elsey N, Engelage J, Eppley G, Esha R, Esumi S, Evdokimov O, Ewigleben J, Eyser O, Fatemi R, Fazio S, Federic P, Fedorisin J, Feng Y, Filip P, Finch E, Fisyak Y, Fulek L, Gagliardi CA, Galatyuk T, Geurts F, Gibson A, Grosnick D, Gupta A, Guryn W, Hamad AI, Hamed A, Harris JW, He L, Heppelmann S, Heppelmann S, Herrmann N, Holub L, Hong Y, Horvat S, Huang B, Huang HZ, Huang SL, Huang T, Huang X, Humanic TJ, Huo P, Igo G, Jacobs WW, Jentsch A, Jia J, Jiang K, Jowzaee S, Ju X, Judd EG, Kabana S, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Kikoła DP, Kim C, Kinghorn TA, Kisel I, Kisiel A, Kocan M, Kochenda L, Kosarzewski LK, Kramarik L, Kravtsov P, Krueger K, Mudiyanselage NK, Kumar L, Elayavalli RK, Kwasizur JH, Lacey R, Landgraf JM, Lauret J, Lebedev A, Lednicky R, Lee JH, Li C, Li W, Li W, Li X, Li Y, Liang Y, Licenik R, Lin T, Lipiec A, Lisa MA, Liu F, Liu H, Liu P, Liu P, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo S, Luo X, Ma GL, Ma L, Ma R, Ma YG, Magdy N, Majka R, Mallick D, Margetis S, Markert C, Matis HS, Matonoha O, Mazer JA, Meehan K, Mei JC, Minaev NG, Mioduszewski S, Mishra D, Mohanty B, Mondal MM, Mooney I, Moravcova Z, Morozov DA, Nasim M, Nayak K, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nogach LV, Nonaka T, Odyniec G, Ogawa A, Oh K, Oh S, Okorokov VA, Page BS, Pak R, Panebratsev Y, Pawlik B, Pei H, Perkins C, Pinter RL, Pluta J, Porter J, Posik M, Pruthi NK, Przybycien M, Putschke J, Quintero A, Radhakrishnan SK, Ramachandran S, Ray RL, Reed R, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Salur S, Sandweiss J, Schambach J, Schmidke WB, Schmitz N, Schweid BR, Seck F, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Shen F, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Siejka S, Sikora R, Simko M, Singha S, Smirnov D, Smirnov N, Solyst W, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stewart DJ, Strikhanov M, Stringfellow B, Suaide AAP, Sugiura T, Sumbera M, Summa B, Sun XM, Sun Y, Sun Y, Surrow B, Svirida DN, Szymanski P, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Timmins AR, Todoroki T, Tokarev M, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Tsai OD, Tu B, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vasiliev AN, Vassiliev I, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang P, Wang Y, Wang Y, Webb JC, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu Y, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu YF, Xu Z, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yoo IK, Zbroszczyk H, Zha W, Zhang D, Zhang L, Zhang S, Zhang S, Zhang XP, Zhang Y, Zhang Z, Zhao J, Zhong C, Zhou C, Zhu X, Zhu Z, Zurek MK, Zyzak M. Observation of Excess J/ψ Yield at Very Low Transverse Momenta in Au+Au Collisions at sqrt[s_{NN}]=200 GeV and U+U Collisions at sqrt[s_{NN}]=193 GeV. PHYSICAL REVIEW LETTERS 2019; 123:132302. [PMID: 31697545 DOI: 10.1103/physrevlett.123.132302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 07/21/2019] [Indexed: 06/10/2023]
Abstract
We report on the first measurements of J/ψ production at very low transverse momentum (p_{T}<0.2 GeV/c) in hadronic Au+Au collisions at sqrt[s_{NN}]=200 GeV and U+U collisions at sqrt[s_{NN}]=193 GeV. Remarkably, the inferred nuclear modification factor of J/ψ at midrapidity in Au+Au (U+U) collisions reaches about 24 (52) for p_{T}<0.05 GeV/c in the 60%-80% collision centrality class. This noteworthy enhancement cannot be explained by hadronic production accompanied by cold and hot medium effects. In addition, the dN/dt distribution of J/ψ for the very low p_{T} range is presented for the first time. The distribution is consistent with that expected from the Au nucleus and shows a hint of interference. Comparison of the measurements to theoretical calculations of coherent production shows that the excess yield can be described reasonably well and reveals a partial disruption of coherent production in semicentral collisions, perhaps due to the violent hadronic interactions. Incorporating theoretical calculations, the results strongly suggest that the dramatic enhancement of J/ψ yield observed at extremely low p_{T} originates from coherent photon-nucleus interactions. In particular, coherently produced J/ψ's in violent hadronic collisions may provide a novel probe of the quark-gluon plasma.
Collapse
|
143
|
Ning T, Shao J, Zhang X, Luo X, Huang X, Wu H, Xu S, Wu B, Ma D. Ageing affects the proliferation and mineralization of rat dental pulp stem cells under inflammatory conditions. Int Endod J 2019; 53:72-83. [PMID: 31419325 DOI: 10.1111/iej.13205] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Accepted: 08/13/2019] [Indexed: 02/06/2023]
Abstract
AIM To comparatively evaluate changes in the proliferation and mineralization abilities of dental pulp stem cells (DPSCs) from juvenile and adult rats in a lipopolysaccharide (LPS)-induced inflammatory microenvironment to provide a theoretical basis for the age-related differences observed in DPSCs during repair of inflammatory injuries. METHODOLOGY DPSCs were isolated from juvenile (JDPSCs) and adult rats (ADPSCs), and senescence-associated β-galactosidase staining was used to compare senescence between JDPSCs and ADPSCs. Effects of LPS on JDPSCs and ADPSCs proliferation were investigated by cell counting kit-8 assays and flow cytometry. Alizarin red staining, quantitative reverse transcription polymerase chain reaction and Western blot assay were used to examine the effects of LPS on mineralization-related genes and proteins in JDPSCs and ADPSCs. Immunohistochemistry was used to compare interleukin-1β (IL-1β) and osteocalcin (OCN) expression in the pulpitis model. Unpaired Student's t-tests and one-way anova were used for statistical analysis. RESULTS DPSCs were isolated from juvenile and adult rat dental pulp tissues. At low concentrations (0.1-1 μg mL-1 ), LPS significantly promoted the proliferation of JDPSCs (P < 0.01) and ADPSCs (P < 0.01 or P < 0.05), with the effect being stronger in JDPSCs than in ADPSCs. In addition, mineralized nodules and the expression of mineralization-related genes (OCN, DSPP, ALP, BSP) increased significantly after stimulation with LPS (0.5 μg mL-1 ) in JDPSCs and ADPSCs (P < 0.01 or P < 0.05), and JDPSCs displayed a more obvious increase than ADPSCs. Western blots revealed OCN and ALP expression levels in JDPSCs treated with LPS were significantly upregulated (P < 0.05); meanwhile, ALP expression in ADPSCs increased slightly but significantly (P < 0.05), and OCN expression was not affected. Finally, IL-1β expression was significantly higher (P < 0.05) and OCN expression was significantly lower (P < 0.05) in the inflamed dental pulp of adult rats than in juvenile rats. CONCLUSIONS A certain degree of inflammatory stimulation promoted the proliferation and mineralization of DPSCs; however, this effect declined with age. The DPSCs of adult donors in an inflammatory microenvironment have a weaker repair ability than that of juvenile donors, who are better candidates for tissues damage repair.
Collapse
|
144
|
Shang S, Ye J, Dou W, Luo X, Qu J, Zhu Q, Zhang H, Wu J. Validation of Zero TE-MRA in the Characterization of Cerebrovascular Diseases: A Feasibility Study. AJNR Am J Neuroradiol 2019; 40:1484-1490. [PMID: 31467242 DOI: 10.3174/ajnr.a6173] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 07/02/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND PURPOSE Zero TE-MRA is less sensitive to field heterogeneity, complex flow, and acquisition noise. This study aimed to prospectively validate the feasibility of zero TE-MRA for cerebrovascular diseases assessment, compared with TOF-MRA. MATERIALS AND METHODS Seventy patients suspected of having cerebrovascular disorders were recruited. Sound levels were estimated for each MRA subjectively and objectively in different modes. MRA image quality was estimated by 2 neuroradiologists. The degree of stenosis (grades 0-4) and the z-diameter of aneurysms (tiny group ≤3 mm and large group >3 mm) were measured for further quantitative analysis. CTA was used as the criterion standard. RESULTS Zero TE-MRA achieved significantly lower subjective perception and objective noise reduction (37.53%). Zero TE-MRA images showed higher signal homogeneity (3.29 ± 0.59 versus 3.04 ± 0.43) and quality of venous signal suppression (3.67 ± 0.47 versus 2.75 ± 0.46). The intermodality agreement was higher for zero TE-MRA than for TOF-MRA (zero TE, 0.90; TOF, 0.81) in the grading of stenosis. Zero TE-MRA had a higher correlation than TOF-MRA (zero TE, 0.84; TOF, 0.74) in the tiny group and a higher consistency with CTA (intraclass correlation coefficient, 0.83; intercept, -0.5084-1.1794; slope -0.4952 to -0.2093) than TOF-MRA (intraclass correlation coefficient, 0.64; intercept, 0.7000-2.6133; slope -1.0344 to -0.1923). Zero TE-MRA and TOF-MRA were comparable in the large group. Zero TE-MRA had more accurate details than TOF-MRA of AVM and Moyamoya lesions. CONCLUSIONS Compared with TOF-MRA, zero TE-MRA achieved more robust performance in depicting cerebrovascular diseases. Therefore, zero TE-MRA was shown to be a promising MRA technique for further routine application in the clinic in patients with cerebrovascular diseases.
Collapse
|
145
|
Xia WG, Abouelezz KFM, Fouad AM, Chen W, Ruan D, Wang S, Azzam MMM, Luo X, Fan QL, Zhang YN, Zheng CT. Productivity, reproductive performance, and fat deposition of laying duck breeders in response to concentrations of dietary energy and protein. Poult Sci 2019; 98:3729-3738. [DOI: 10.3382/ps/pez061] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 02/14/2019] [Indexed: 12/17/2022] Open
|
146
|
Gao Z, Luo X, Liu L, Lin L, Tong M, Yang T. Recombinant
Treponema pallidum
protein Tp47 induces angiogenesis by modulating the matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in endothelial cells. J Eur Acad Dermatol Venereol 2019; 33:1958-1970. [PMID: 31166625 DOI: 10.1111/jdv.15725] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Accepted: 05/08/2019] [Indexed: 12/20/2022]
|
147
|
Asma B, Zhao F, Cai X, Luo X. Mining and Polymorphic Analysis of Di-Nucleotide Microsatellites from Yak Genome. RUSS J GENET+ 2019. [DOI: 10.1134/s1022795419070044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
148
|
Adams C, Alrashed M, An R, Anthony J, Asaadi J, Ashkenazi A, Auger M, Balasubramanian S, Baller B, Barnes C, Barr G, Bass M, Bay F, Bhat A, Bhattacharya K, Bishai M, Blake A, Bolton T, Camilleri L, Caratelli D, Caro Terrazas I, Carr R, Castillo Fernandez R, Cavanna F, Cerati G, Chen H, Chen Y, Church E, Cianci D, Cohen E, Collin G, Conrad J, Convery M, Cooper-Troendle L, Crespo-Anadón J, Del Tutto M, Devitt D, Diaz A, Duffy K, Dytman S, Eberly B, Ereditato A, Escudero Sanchez L, Esquivel J, Evans J, Fadeeva A, Fitzpatrick R, Fleming B, Franco D, Furmanski A, Garcia-Gamez D, Genty V, Goeldi D, Gollapinni S, Goodwin O, Gramellini E, Greenlee H, Grosso R, Guenette R, Guzowski P, Hackenburg A, Hamilton P, Hen O, Hewes J, Hill C, Horton-Smith G, Hourlier A, Huang EC, James C, Jan de Vries J, Ji X, Jiang L, Johnson R, Joshi J, Jostlein H, Jwa YJ, Karagiorgi G, Ketchum W, Kirby B, Kirby M, Kobilarcik T, Kreslo I, Lepetic I, Li Y, Lister A, Littlejohn B, Lockwitz S, Lorca D, Louis W, Luethi M, Lundberg B, Luo X, Marchionni A, Marcocci S, Mariani C, Marshall J, Martin-Albo J, Martinez Caicedo D, Mastbaum A, Meddage V, Mettler T, Mistry K, Mogan A, Moon J, Mooney M, Moore C, Mousseau J, Murphy M, Murrells R, Naples D, Nienaber P, Nowak J, Palamara O, Pandey V, Paolone V, Papadopoulou A, Papavassiliou V, Pate S, Pavlovic Z, Piasetzky E, Porzio D, Pulliam G, Qian X, Raaf J, Rafique A, Ren L, Rochester L, Ross-Lonergan M, Rudolf von Rohr C, Russell B, Scanavini G, Schmitz D, Schukraft A, Seligman W, Shaevitz M, Sharankova R, Sinclair J, Smith A, Snider E, Soderberg M, Söldner-Rembold S, Soleti S, Spentzouris P, Spitz J, John JS, Strauss T, Sutton K, Sword-Fehlberg S, Szelc A, Tagg N, Tang W, Terao K, Thomson M, Thornton R, Toups M, Tsai YT, Tufanli S, Usher T, Van De Pontseele W, Van de Water R, Viren B, Weber M, Wei H, Wickremasinghe D, Wierman K, Williams Z, Wolbers S, Wongjirad T, Woodruff K, Yang T, Yarbrough G, Yates L, Zeller G, Zennamo J, Zhang C. First measurement of
νμ
charged-current
π0
production on argon with the MicroBooNE detector. Int J Clin Exp Med 2019. [DOI: 10.1103/physrevd.99.091102] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
149
|
Adam J, Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Anderson DM, Aoyama R, Aparin A, Arkhipkin D, Aschenauer EC, Ashraf MU, Atetalla F, Attri A, Averichev GS, Bai X, Bairathi V, Barish K, Bassill AJ, Behera A, Bellwied R, Bhasin A, Bhati AK, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Brandenburg JD, Brandin AV, Brown D, Bryslawskyj J, Bunzarov I, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Cebra D, Chakaberia I, Chaloupka P, Chan BK, Chang FH, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen JH, Chen X, Chen X, Cheng J, Cherney M, Christie W, Contin G, Crawford HJ, Csanad M, Das S, Dedovich TG, Deppner IM, Derevschikov AA, Didenko L, Dilks C, Dong X, Drachenberg JL, Dunlop JC, Efimov LG, Elsey N, Engelage J, Eppley G, Esha R, Esumi S, Evdokimov O, Ewigleben J, Eyser O, Fatemi R, Fazio S, Federic P, Federicova P, Fedorisin J, Filip P, Finch E, Fisyak Y, Flores CE, Fulek L, Gagliardi CA, Galatyuk T, Geurts F, Gibson A, Grosnick D, Gunarathne DS, Guo Y, Gupta A, Guryn W, Hamad AI, Hamed A, Harlenderova A, Harris JW, He L, Heppelmann S, Heppelmann S, Herrmann N, Hirsch A, Holub L, Hong Y, Horvat S, Huang B, Huang HZ, Huang SL, Huang T, Huang X, Humanic TJ, Huo P, Igo G, Jacobs WW, Jentsch A, Jia J, Jiang K, Jowzaee S, Ju X, Judd EG, Kabana S, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kikoła DP, Kim C, Kinghorn TA, Kisel I, Kisiel A, Kochenda L, Kosarzewski LK, Kraishan AF, Kramarik L, Krauth L, Kravtsov P, Krueger K, Kulathunga N, Kumar L, Kunnawalkam Elayavalli R, Kvapil J, Kwasizur JH, Lacey R, Landgraf JM, Lauret J, Lebedev A, Lednicky R, Lee JH, Li C, Li W, Li X, Li Y, Liang Y, Lidrych J, Lin T, Lipiec A, Lisa MA, Liu F, Liu H, Liu P, Liu P, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomnitz M, Longacre RS, Luo S, Luo X, Ma GL, Ma L, Ma R, Ma YG, Magdy N, Majka R, Mallick D, Margetis S, Markert C, Matis HS, Matonoha O, Mazer JA, Meehan K, Mei JC, Minaev NG, Mioduszewski S, Mishra D, Mohanty B, Mondal MM, Mooney I, Morozov DA, Nasim M, Negrete JD, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nogach LV, Nonaka T, Odyniec G, Ogawa A, Oh K, Oh S, Okorokov VA, Olvitt D, Page BS, Pak R, Panebratsev Y, Pawlik B, Pei H, Perkins C, Pinter RL, Pluta J, Porter J, Posik M, Pruthi NK, Przybycien M, Putschke J, Quintero A, Radhakrishnan SK, Ramachandran S, Ray RL, Reed R, Ritter HG, Roberts JB, Rogachevskiy OV, Romero JL, Ruan L, Rusnak J, Rusnakova O, Sahoo NR, Sahu PK, Salur S, Sandweiss J, Schambach J, Schmah AM, Schmidke WB, Schmitz N, Schweid BR, Seck F, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Shen F, Shen WQ, Shi SS, Shou QY, Sichtermann EP, Siejka S, Sikora R, Simko M, Singh J, Singha S, Smirnov D, Smirnov N, Solyst W, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stewart DJ, Strikhanov M, Stringfellow B, Suaide AAP, Sugiura T, Sumbera M, Summa B, Sun XM, Sun X, Sun Y, Surrow B, Svirida DN, Szymanski P, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tokarev M, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Tsai OD, Tu B, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vasiliev AN, Vassiliev I, Videbæk F, Vokal S, Voloshin SA, Vossen A, Wang F, Wang G, Wang P, Wang Y, Wang Y, Webb JC, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu Y, Xiao ZG, Xie G, Xie W, Xu J, Xu N, Xu QH, Xu YF, Xu Z, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yoo IK, Yu N, Zbroszczyk H, Zha W, Zhang J, Zhang J, Zhang L, Zhang S, Zhang S, Zhang XP, Zhang Y, Zhang Z, Zhao J, Zhong C, Zhou C, Zhu X, Zhu Z, Zyzak M. Azimuthal Harmonics in Small and Large Collision Systems at RHIC Top Energies. PHYSICAL REVIEW LETTERS 2019; 122:172301. [PMID: 31107064 DOI: 10.1103/physrevlett.122.172301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 03/26/2019] [Indexed: 06/09/2023]
Abstract
The first (v_{1}^{fluc}), second (v_{2}), and third (v_{3}) harmonic coefficients of the azimuthal particle distribution at midrapidity are extracted for charged hadrons and studied as a function of transverse momentum (p_{T}) and mean charged particle multiplicity density ⟨N_{ch}⟩ in U+U (sqrt[s_{NN}]=193 GeV), Au+Au, Cu+Au, Cu+Cu, d+Au, and p+Au collisions at sqrt[s_{NN}]=200 GeV with the STAR detector. For the same ⟨N_{ch}⟩, the v_{1}^{fluc} and v_{3} coefficients are observed to be independent of the collision system, while v_{2} exhibits such a scaling only when normalized by the initial-state eccentricity (ϵ_{2}). The data also show that ln(v_{2}/ϵ_{2}) scales linearly with ⟨N_{ch}⟩^{-1/3}. These measurements provide insight into initial-geometry fluctuations and the role of viscous hydrodynamic attenuation on v_{n} from small to large collision systems.
Collapse
|
150
|
Bi R, Yin Q, Luo X, Li Y, Zhu S. Posterior airway change after mandibular distraction osteogenesis in temporomandibular joint ankylosis patients: a retrospective study. Int J Oral Maxillofac Surg 2019. [DOI: 10.1016/j.ijom.2019.03.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|